The updates are as follows;

• Addition of the immune-mediated adverse reactions sclerosing cholangitis, arthritis, polymyalgia rheumatica, and Sjogren’s syndrome based on post-marketing data and literature
• Deletion of the word “ Alert” from the document name, Patient Alert Card

This change is triggered by the approval of the Type II variation in UK PLGB 11648/0262 – 0037 and introduction of the new version of the RMP v 7.3 for Bavencio 20 mg/ml concentrate for solution for infusion.